A clinical trial titled "The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia" was listed with a status update dated July 20, 2026. The trial registry identifies the study as NCT07390240 and lists its current status as recruiting.
No phase was specified for this study in the available record. The trial focuses on how monoallelic variants in the ALPL gene relate to the natural course of hypophosphatasia among patients in Russia.
This update reflects the trial's recruitment status as of the listed date. No results have been posted, and this brief does not report on efficacy, safety, or outcomes. The registry entry does not provide additional details on enrollment criteria, timeline, or sponsor beyond what is stated here.
Teriparatide is an approved compound relevant to bone metabolism research. Readers interested in background information can consult the compound overview for further context on teriparatide.